Hexapro-based SARS-CoV-2 vaccine  (Vaxxas/University of Queensland)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameHexapro-based SARS-CoV-2 vaccine  (Vaxxas/University of Queensland)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Queensland
China Registration ClassN/A

Develop Information

Active CompaniesVaxxas Pty Ltd
Inactive CompaniesThe University Of Queensland
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A